MURA-7012 / Mural Oncology - LARVOL DELTA

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts (GlobeNewswire) - "The company expanded its pipeline in Q4 2024, by nominating two development candidates, one for its interleukin-18 (IL-18) program and one for its IL-12 program. MURA-8518 is designed to be a half-life extended, binding protein-resistant IL-18 in order to overcome the native cytokine’s limitations as a therapeutic. Mural expects to submit an Investigational New Drug (IND) Application or Clinical Trial Application (CTA) for a phase 1 trial of MURA-8518 in Q4 2025. MURA-7012 is comprised of targeted split IL-12 sub-units that preferentially self-assemble at the tumor site and are designed to limit systemic exposure."

IND • Pipeline update • Oncology

Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits (Saturday, Nov. 9: Abstract #1300) (GlobeNewswire) - "Mural Oncology...shared...poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....In murine models, increasing the interval time between subunit injections or reducing the dose level of the second subunit effectively modulated serum drug concentration while maintaining IL-12 levels in the tumor. Pharmacokinetics and pharmacodynamics were also assessed in non-human primates, where the inactive subunits were assembled and formed functional IL-12p70 in the periphery....Mural plans to nominate a development candidate for its IL-12 program by the end of 2024."

Pipeline update • PK/PD data • Preclinical • Oncology • Solid Tumor

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Mural Oncology plc...shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting....Abstract #4066:...Mural’s protein engineering approach aims to mitigate IL-12's hallmark toxicity by splitting the heterodimer into two inactive monomers: IL-12p35 and IL-12p40. These individual subunits are separately fused to two non-competitive antibody fragments....In vivo analysis demonstrated that targeting both subunits resulted in the greatest accumulation and retention of IL-12p70 complex in the tumor."

Preclinical • Oncology

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire) - "Mural Oncology will present preclinical IL-18 and IL-12 data for the first time at the upcoming AACR conference. The company intends to nominate development candidates for these engineered IL-18 and IL-12 therapies later this year."

Pipeline update • Preclinical • Oncology